|
1
|
Gelderblom H, Hogendoorn PC, Dijkstra SD,
van Rijswijk CS, Krol AD, Taminiau AH and Bovée JV: The clinical
approach towards chondrosarcoma. Oncologist. 13:320–329. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Xu J, Li D, Xie L, Tang S and Guo W:
Mesenchymal chondrosarcoma of bone and soft tissue: A systematic
review of 107 patients in the past 20 years. PLoS One.
10:e01222162015. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Wagner MJ, Livingston JA, Patel SR and
Benjamin RS: Chemotherapy for bone sarcoma in adults. J Oncol
Pract. 12:208–216. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Onishi AC, Hincker AM and Lee FY:
Surmounting chemotherapy and radioresistance in chondrosarcoma:
Molecular mechanisms and therapeutic targets. Sarcoma.
2011:3815642011. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Italiano A, Mir O, Cioffi A, Palmerini E,
Piperno-Neumann S, Perrin C, Chaigneau L, Penel N, Duffaud F, Kurtz
JE, et al: Advanced chondrosarcomas: Role of chemotherapy and
survival. Ann Oncol. 24:2916–2922. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Rosati A, Graziano V, De Laurenzi V,
Pascale M and Turco MC: BAG3: A multifaceted protein that regulates
major cell pathways. Cell Death Dis. 2:e1412011. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Fuchs M, Poirier DJ, Seguin SJ, Lambert H,
Carra S, Charette SJ and Landry J: Identification of the key
structural motifs involved in HspB8/HspB6-Bag3 interaction. Biochem
J. 425:245–255. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Li X, Colvin T, Rauch JN, Acosta-Alvear D,
Kampmann M, Dunyak B, Hann B, Aftab BT, Murnane M, Cho M, et al:
Validation of the Hsp70-Bag3 protein-protein interaction as a
potential therapeutic target in cancer. Mol Cancer Ther.
14:642–648. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Colvin TA, Gabai VL, Gong J, Calderwood
SK, Li H, Gummuluru S, Matchuk ON, Smirnova SG, Orlova NV,
Zamulaeva IA, et al: Hsp70-Bag3 interactions regulate
cancer-related signaling networks. Cancer Res. 74:4731–4740. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Kong DH, Zhang Q, Meng X, Zong ZH, Li C,
Liu BQ, Guan Y and Wang HQ: BAG3 sensitizes cancer cells exposed to
DNA damaging agents via direct interaction with GRP78. Biochim
Biophys Acta. 1833:3245–3253. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Habata S, Iwasaki M, Sugio A, Suzuki M,
Tamate M, Satohisa S, Tanaka R and Saito T: BAG3-mediated Mcl-1
stabilization contributes to drug resistance via interaction with
USP9X in ovarian cancer. Int J Oncol. 49:402–410. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Maruyama K, Ochiai A, Akimoto S, Nakamura
S, Baba S, Moriya Y and Hirohashi S: Cytoplasmic beta-catenin
accumulation as a predictor of hematogenous metastasis in human
colorectal cancer. Oncology. 59:302–309. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Komori T: Regulation of skeletal
development by the Runx family of transcription factors. J Cell
Biochem. 95:445–453. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Banerjee C, McCabe LR, Choi JY, Hiebert
SW, Stein JL, Stein GS and Lian JB: Runt homology domain proteins
in osteoblast differentiation: AML3/CBFA1 is a major component of a
bone-specific complex. J Cell Biochem. 66:1–8. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Lemieux E, Cagnol S, Beaudry K, Carrier J
and Rivard N: Oncogenic KRAS signalling promotes the Wnt/β-catenin
pathway through LRP6 in colorectal cancer. Oncogene. 34:4914–4927.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Suzuki M, Iwasaki M, Sugio A, Hishiya A,
Tanaka R, Endo T, Takayama S and Saito T: BAG3 (BCL2-associated
athanogene 3) interacts with MMP-2 to positively regulate invasion
by ovarian carcinoma cells. Cancer Lett. 303:65–71. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Shi H, Xu H, Li Z, Zhen Y, Wang B, Huo S,
Xiao R and Xu Z: BAG3 regulates cell proliferation, migration and
invasion in human colorectal cancer. Tumour Biol. 37:5591–5597.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Staibano S, Mascolo M, Di Benedetto M,
Vecchione ML, Ilardi G, Di Lorenzo G, Autorino R, Salerno V, Morena
A, Rocco A, et al: BAG3 protein delocalisation in prostate
carcinoma. Tumour Biol. 31:461–469. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Falco A, Rosati A, Festa M, Basile A, De
Marco M, d'Avenia M, Pascale M, Dal Piaz F, Tavano F, Di Mola FF,
et al: BAG3 is a novel serum biomarker for pancreatic
adenocarcinomas. Am J Gastroenterol. 108:1178–1180. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Felzen V, Hiebel C, Koziollek-Drechsler I,
Reißig S, Wolfrum U, Kögel D, Brandts C, Behl C and Morawe T:
Estrogen receptor α regulates non-canonical autophagy that provides
stress resistance to neuroblastoma and breast cancer cells and
involves BAG3 function. Cell Death Dis. 6:e18122015. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Chiappetta G, Ammirante M, Basile A,
Rosati A, Festa M, Monaco M, Vuttariello E, Pasquinelli R, Arra C,
Zerilli M, et al: The antiapoptotic protein BAG3 is expressed in
thyroid carcinomas and modulates apoptosis mediated by tumor
necrosis factor-related apoptosis-inducing ligand. J Clin
Endocrinol Metab. 92:1159–1163. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Chen C, Zhou H, Zhang X, Ma X, Liu Z and
Liu X: Elevated levels of Dickkopf-1 are associated with
beta-catenin accumulation and poor prognosis in patients with
chondrosarcoma. PLoS One. 9:e1054142014. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Nowicki A, Sporny S and Duda-Szymanska J:
β-catenin as a prognostic factor for prostate cancer (PCa). Central
European J Urol. 65:119–123. 2012. View Article : Google Scholar
|
|
24
|
Calaf GM, Alvarado ME and Hei TK: Beta
catenin is associated with breast cancer progression in vitro. Int
J Oncol. 26:913–921. 2005.PubMed/NCBI
|
